Filters
For individuals who completed treatment for pulmonary tuberculosis (TB), vaccination with H56:IC31 does not appear to reduce the risk of disease recurrence, according to a phase 2b trial.
New drug applications approved by US FDA as of 16-28 February 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The introduction of pneumococcal conjugate vaccines (PCV) into Singapore's National Childhood Immunisation Schedule (NCIS) has reduced the incidence of invasive pneumococcal disease (IPD) in children by nearly a third, as reported in a study.
Awareness about human papillomavirus (HPV) infection in males and the benefits of vaccination on both genders is low among young adults, reveals a Singapore study.
In children and adolescents who have contracted COVID-19, gastrointestinal (GI) tract symptoms may remain for up to 2 years, as reported in a large retrospective study.
Paediatric post-COVID syndrome (pPCS) brings a substantial socio-educational burden that must be included in medical, social, and educational care, suggests a study.
New drug applications approved by US FDA as of 1-15 February 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Tetracycline demonstrates superior clinical efficacy to that of macrolide in children with macrolide-resistant Mycoplasma pneumoniae (MRMP) pneumonia, a study has shown.
Treatment with ivermectin for mild-to-moderate COVID-19 does not appear to reduce recovery time as compared with placebo, according to data from the ongoing ACTIV-6* study.
Treatment with high-dose sulbactam leads to higher mid-dosing (Cmid) and pharmacokinetic-pharmacodynamic (PK-PD) achievement in paediatric patients, reports a study.
